Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Dean Andrew Regier, Nick Bansback, Anne Dar Santos, Carlo A. Marra*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Original languageEnglish
Pages (from-to)155-169
Number of pages15
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2007

Keywords

  • Adalimumab
  • Ankylosing spondylitis
  • Biological response modifier
  • Cost-effectiveness analysis
  • Etanercept
  • Infliximab
  • Psociatic arthritis
  • Rheumatoid arthritis

Fingerprint

Dive into the research topics of 'Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis'. Together they form a unique fingerprint.

Cite this